Trial Updates
KESETT – New Resource in the Workbench
We have added a new resource to the KESETT workbench. You can find the archive of the slides presented at the monthly SIREN study coordinator meeting in the workbench under …
KESETT – Welcoming Our New Site Manager
Please join the SIREN CCC in welcoming our new KESETT Site Manager, Vincent Cervantes. Vincent will be the primary point of contact for KESETT site management questions. His contact is …
Overview
Generalized convulsive status epilepticus (long-lasting convulsive seizures) is a dangerous but common neurologic emergency; it can cause respiratory depression and permanent brain damage. KESETT is a phase III randomized, double-blind clinical trial to test whether ketamine (1 or 3 mg/Kg) added to standard therapy, levetiracetam (60mg/Kg), is more effective than levetiracetam alone in treating status epilepticus after benzodiazepines have failed.
Contact
Emergency 24-Hour Study Hotline:
To be announced
Education (training, website access, material development, technical support):
Courtney Miller (coraymon@umich.edu) – Education Coordinator, or siren-contact@umich.edu
WebDCU Support (user account requests, technical support, CRF completion):
Sara Meyer (butlers@musc.edu) (843) 792-1599 & Riley Luckmann (luckmann@musc.edu) (843) 792-1599
Site Management & General Inquiries:
Vincent Cervantes (vcervant@umich.edu) or KESETT-contact@umich.edu
Finances:
Valerie Stevenson (vwillis@umich.edu)